etylcysteine is recommended for at-risk patients,
given its low cost, safety proﬁle, and mild protective
effect. However, a randomized trial of N-acetylcysteine
did not reduce the incidence of CIN after EVAR.133
Recent evidence suggests that statin therapy may be of
beneﬁt in preventing CIN. For example, two studies

Journal of Vascular Surgery

Chaikof et al

21

